Meeting Banner
Abstract #1121

Assessing Metabolic Intervention in Acute Myeloid Leukemia with a Glutaminase Inhibitor by Hyperpolarized Magnetic Resonance

Niki Zacharias Millward 1,2, Sriram Shanmugavelandy1, Jaehyuk Lee 1, Natalia Baran3, Juliana Velez3, Prasanta Dutta 1, Marina Konopleva 3, and Pratip Bhattacharya1

1Cancer Systems Imaging, MD Anderson Cancer Center, Houston, TX, United States, 2Bioengineering, Rice University, Houston, TX, 3Leukemia, MD Anderson Cancer Center, Houston, TX, United States

Acute myeloid leukemia (AML) is glutamine addicted cancer. We determined if hyperpolarized pyruvate could be utilized to detect in vivo metabolic changes in AML (OCI-AML3 cell line) bearing mice after CB839 (glutaminase inhibitor) treatment. We found a reduction of pyruvate to lactate conversion after treatment. In vitro analysis of OCI-AML3 reveal that NADH/NAD+ ratio, ATP, hydrogen peroxide levels and respiratory capacity reduce in CB839 treated cells compared to vehicle controls. Our data supports the hypothesis that in AML glutamine generates reducing equivalences by the citric acid cycle and inhibiting this process with CB839 reduces the rate of conversion of pyruvate to lactate.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.

Keywords